What's Happening?
Him & Hers, a telehealth provider, has announced that eligible users can now access the full range of FDA-approved GLP-1 medications through its platform. This includes prescriptions for Eli Lilly's Zepbound, Mounjaro, and oral Foundayo, which can be
sent to the LillyDirect pharmacy for self-pay pricing. The platform also offers Wegovy pills and injections, as well as Ozempic injections, with prices starting from $149 per month for Foundayo pills and up to $1,899 per month for Mounjaro. The company aims to provide a diverse range of treatment options to support customers' health journeys. This expansion follows a partnership with Novo Nordisk, which began nearly a year ago, to offer high-demand weight loss drugs.
Why It's Important?
The inclusion of FDA-approved GLP-1 medications on the Him & Hers platform represents a significant development in telehealth services, particularly in the realm of weight management and obesity treatment. These medications, such as Wegovy and Ozempic, are in high demand due to their effectiveness in weight loss. By offering these drugs, Him & Hers is enhancing accessibility for patients who may benefit from these treatments but face barriers in traditional healthcare settings. This move could potentially lead to increased competition among telehealth providers and drive innovation in digital health services. Additionally, the partnership with Novo Nordisk highlights the growing collaboration between pharmaceutical companies and telehealth platforms, which could reshape how patients access medications.
What's Next?
As Him & Hers expands its offerings, it may attract more users seeking convenient access to weight loss medications. The company could further develop its platform to include additional health services and medications, enhancing its role in the telehealth industry. Stakeholders, including other telehealth providers and pharmaceutical companies, may respond by forming similar partnerships to capitalize on the growing demand for digital health solutions. Regulatory bodies might also take interest in monitoring the impact of such expansions on patient safety and drug accessibility.
